Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172394 | 0.96 | HPGD (0.43) | POLBHPGDPDE4BKMT2ARAB9A | |
| SCHEMBL19728192 | 0.90 | KMT2A (0.40) | POLBHPGDPDE4BKMT2ARAB9A | |
| SCHEMBL16809943 | 0.88 | POLB (0.41) | POLBHPGDPDE4BKMT2ARAB9A | |
| SCHEMBL9999753 | 0.88 | KMT2A (0.38) | POLBHPGDPDE4BKMT2ARAB9A | |
| SCHEMBL22277282 | 0.86 | HPGD (0.44) | POLBHPGDKMT2ARAB9AMEN1 | |
| SCHEMBL18012158 | 0.86 | HPGD (0.44) | POLBHPGDKMT2ARAB9AMEN1 | |
| SCHEMBL9562372 | 0.85 | POLB (0.45) | POLBHPGDPDE4BKMT2ARAB9A | |
| SCHEMBL9562374 | 0.85 | POLB (0.45) | POLBHPGDPDE4BKMT2ARAB9A | |
| SCHEMBL22277620 | 0.84 | HPGD (0.40) | POLBHPGDPDE4BKMT2ARAB9A | |
| SCHEMBL10091260 | 0.84 | ESR1 (0.47) | POLBHPGDKMT2ARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357637-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| US-11802243-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2023-10-31 | — | — | US | disclosed |
| US-11795398-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same and compounds | MERCK PATENT GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20230323209-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| US-20230295510-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230295511-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20180216006-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | US | disclosed |
| US-20180216005-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | US | disclosed |
| US-20180163136-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-06-14 | — | — | US | disclosed |
| US-20180142152-A1 | COMPOUNDS FOR THE HOMEOTROPIC ALIGNMENT OF LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2018-05-24 | — | — | US | disclosed |
| EP-2239310-A1 | Liquid crystal medium and liquid crystal display | Merck Patent GmbH (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-20100252777-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-07 | — | — | US | disclosed |
| EP-2199362-A2 | Liquid crystalline medium | Merck Patent GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2010057575-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2010-05-27 | — | — | WO | disclosed |
| US-20100108945-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-05-06 | — | — | US | disclosed |
| EP-2182046-A1 | Liquid-crystalline medium and liquid crystal display | Merck Patent GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| US-20090309066-A1 | Mixture of polar compounds containing cyclohexane and benzene rings some of which are vinylene-linked, especially containing fluoroalkoxy groups; for electrooptical twisted nematic monitor applications | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009129911-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH, (DE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009115186-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008009417-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180216006-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | VIM, NEFM, AQP1 | POLB 318/4885HPGD 4148/4885PDE4B 350/4885 |
| US-20180216005-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | VIM, NEFM, AQP1 | POLB 264/4885HPGD 4359/4885PDE4B 309/4885 |
| US-20090309066-A1 | Mixture of polar compounds containing cyclohexane and benzene rings some of which are vinylene-linked, especially containing fluoroalkoxy groups; for electrooptical twisted nematic monitor applications | VIM, CDH1, LEF1 | POLB 172/4885HPGD 3765/4885PDE4B 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.